MedTrace Logo

Telmisartan, Amlodipine and Flow Mediated Dilation

NCT01180205 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 576

Last updated 2011-07-12

No results posted yet for this study

Summary

To show superior effects of the combination Telmisartan and Amlodipine (T and A) vs Olmesartan and Hydrochlorothiazide (O and HCTZ) on endothelial dysfunction as measured by flow mediated dilation (FMD) in hypertensive at risk patients beyond bloodpressure BP (equal BP in both arms; target BP \<140/90 mmHg (\<130/80 mmHg for renally impaired and/ or diabetic patients). To investigate the effects of T and A vs O and HCTZ in reducing arterial stiffness and carotid atherosclerotic plaques.

Conditions

Interventions

DRUG

Telmisartan

Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)

DRUG

Amlodipine

Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks

DRUG

Olmesartan medoxomil

Olmesartan 40 mg po for 26 weeks

DRUG

Hydrochlorothiazide

HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks

Sponsors & Collaborators

  • Johannes Gutenberg University Mainz

    lead OTHER

Principal Investigators

  • Stefan Blankenberg, Prof.Dr.med. · Universitätsmedizin Mainz, II.Medizinische Klinik

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01180205 on ClinicalTrials.gov